Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
Meazza C., Galaverna F., Petris M.G., Zama D., La Spina M., Muggeo P., et al. (2021). Prophylaxis with Trimethoprim/Sulfamethoxazole Is Not Necessary in Children with Solid Tumors Treated with Low-medium Intensity Chemotherapy. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL, 40(4), 354-355 [10.1097/INF.0000000000003044].
Prophylaxis with Trimethoprim/Sulfamethoxazole Is Not Necessary in Children with Solid Tumors Treated with Low-medium Intensity Chemotherapy
Zama D.;Cellini M.;Soncini E.;
2021
Abstract
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
